专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090148943A1 AGENT FOR ENHANCING THE PRODUCTION OF CYTOKINES AND/OR CHEMOKINES 审中-公开
标题翻译：用于增强细胞因子和/或细胞因子生产的代理
公开(公告)号：US20090148943A1
公开(公告)日：2009-06-11
申请号：US12265348
申请日：2008-11-05
申请人： Makoto TAKEUCHI , Takanori Okura , Tomoki Tatefuji , Tetsuya Mori , Chikako Arai , Tsunetaka Ohta , Masashi Kurimoto
发明人： Makoto TAKEUCHI , Takanori Okura , Tomoki Tatefuji , Tetsuya Mori , Chikako Arai , Tsunetaka Ohta , Masashi Kurimoto
IPC分类号： C12N5/06
CPC分类号： C07K14/4705 , A61K38/00
摘要： The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3; a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3, where one or more amino acids thereof are deleted or replaced with other amino acid(s) and/or one or more amino acids are added thereunto, without substantially losing the biological activity of the polypeptide.
摘要翻译：本发明的目的是提供有效增强哺乳动物中细胞因子和/或趋化因子的产生的方法。通过提供用于增强细胞因子和/或趋化因子的产生的试剂来解决该问题，所述试剂包含作为有效成分的具有SEQ ID NO：1至3的任一氨基酸序列的多肽; 具有SEQ ID NO：1至3的任何一个氨基酸序列的多肽，其中一个或多个氨基酸被缺失或被其它氨基酸和/或一个或多个氨基酸所取代，而没有基本上丧失了多肽的生物活性。

2. 发明申请

US20070110711A1 Agent for enhancing the production of cytokines and/or chemokines 审中-公开
标题翻译：用于增强细胞因子和/或趋化因子产生的药剂
公开(公告)号：US20070110711A1
公开(公告)日：2007-05-17
申请号：US11583148
申请日：2006-10-19
申请人： Makoto Takeuchi , Takanori Okura , Tomoki Tatefuji , Tetsuya Mori , Chikako Arai , Tsunetaka Ohta , Masashi Kurimoto
发明人： Makoto Takeuchi , Takanori Okura , Tomoki Tatefuji , Tetsuya Mori , Chikako Arai , Tsunetaka Ohta , Masashi Kurimoto
IPC分类号： A61K38/19 , C07K14/52
CPC分类号： C07K14/4705 , A61K38/00
摘要： The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3; a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3, where one or more amino acids thereof are deleted or replaced with other amino acid(s) and/or one or more amino acids are added thereunto, without substantially losing the biological activity of the polypeptide.
摘要翻译：本发明的目的是提供有效增强哺乳动物中细胞因子和/或趋化因子的产生的方法。通过提供用于增强细胞因子和/或趋化因子的产生的试剂来解决该问题，所述试剂包含作为有效成分的具有SEQ ID NO：1至3的任一氨基酸序列的多肽; 具有SEQ ID NO：1至3的任何一个氨基酸序列的多肽，其中一个或多个氨基酸被缺失或被其它氨基酸和/或一个或多个氨基酸加入，而没有基本上丧失了多肽的生物活性。

3. 发明授权

US08187584B2 Human tumor necrosis factor-α mutants 有权
标题翻译：人肿瘤坏死因子-α突变体
公开(公告)号：US08187584B2
公开(公告)日：2012-05-29
申请号：US13205053
申请日：2011-08-08
申请人： Tadanori Mayumi , Yasuo Tsutsumi , Shinsaku Nakagawa , Tsunetaka Ohta
发明人： Tadanori Mayumi , Yasuo Tsutsumi , Shinsaku Nakagawa , Tsunetaka Ohta
IPC分类号： A61K38/19 , C07K14/525
CPC分类号： A61K38/191 , C07K14/525 , Y02A50/411
摘要： The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.
摘要翻译：本发明的目的是提供肿瘤坏死因子突变蛋白，特别是TNF-R1或TNF-R2特异的肿瘤坏死因子突变体蛋白; 肿瘤坏死因子抑制剂; 或含有其作为有效成分的肿瘤坏死因子制剂，其目的是通过提供一种或多种选自第29,31,32,35,146和147位的氨基酸残基的肿瘤坏死因子突变蛋白来解决，或由SEQ ID NO：1的氨基酸序列的N末端第84位至第89位的基团被其它氨基酸残基取代; 肿瘤坏死因子抑制剂; 和含有它作为有效成分的肿瘤坏死因子制剂。

4. 发明授权

US07993636B2 Tumor necrosis factor-alpha mutants 有权
标题翻译：肿瘤坏死因子-α突变体
公开(公告)号：US07993636B2
公开(公告)日：2011-08-09
申请号：US10585296
申请日：2005-01-05
申请人： Tadanori Mayumi , Yasuo Tsutsumi , Shinsaku Nakagawa , Tsunetaka Ohta
发明人： Tadanori Mayumi , Yasuo Tsutsumi , Shinsaku Nakagawa , Tsunetaka Ohta
IPC分类号： C07K14/525
CPC分类号： A61K38/191 , C07K14/525 , Y02A50/411
摘要： The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.
摘要翻译：本发明的目的是提供肿瘤坏死因子突变蛋白，特别是TNF-R1或TNF-R2特异的肿瘤坏死因子突变体蛋白; 肿瘤坏死因子抑制剂; 或含有其作为有效成分的肿瘤坏死因子制剂，其目的是通过提供一种或多种选自第29,31,32,35,146和147位的氨基酸残基的肿瘤坏死因子突变蛋白来解决，或由SEQ ID NO：1的氨基酸序列的N末端第84位至第89位的基团被其它氨基酸残基取代; 肿瘤坏死因子抑制剂; 和含有它作为有效成分的肿瘤坏死因子制剂。

5. 发明授权

US5498697A Protein possessing metastasis-inhibitory activity 失效
标题翻译：蛋白具有转移抑制活性
公开(公告)号：US5498697A
公开(公告)日：1996-03-12
申请号：US127278
申请日：1993-09-27
申请人： Kanso Iwaki , Tsunetaka Ohta , Masashi Kurimoto
发明人： Kanso Iwaki , Tsunetaka Ohta , Masashi Kurimoto
IPC分类号： A61K38/00 , A61P35/00 , A61P35/04 , C07K14/47 , C12N5/06 , C12N15/09 , C12N15/12 , C12P21/02 , C12R1/91 , C07K1/00 , C07H19/00 , C07H21/00 , C07K2/00
CPC分类号： C07K14/4703 , A61K38/00
摘要： Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Guerin and lipopolysaccharide.
摘要翻译：公开了一种新型蛋白质，其分子量为45,000 +/- 5,000，pI 5.7 +/- 0.5，具有癌转移抑制活性。蛋白质可以通过在营养培养基中培养能够产生蛋白质的人细胞，动物细胞和微生物，同时用诸如卡介苗和脂多糖的诱导剂刺激它们来制备。

6. 发明申请

US20110091968A1 MONOCLONAL ANTIBODY SPECIFIC TO BOTH HUMAN INTERFERON-ALPHA SUBTYPE ALPHA 8 AND ITS MUTANT PROTEINS 失效
标题翻译：人类干扰素ALPHA亚型ALPHA 8及其突变蛋白特异性单克隆抗体
公开(公告)号：US20110091968A1
公开(公告)日：2011-04-21
申请号：US12933768
申请日：2009-03-16
申请人： Shigeharu Fukuda , Chie Ushio , Harumi Ariyasu , Tohru Kayano , Toshio Ariyasu , Tsunetaka Ohta
发明人： Shigeharu Fukuda , Chie Ushio , Harumi Ariyasu , Tohru Kayano , Toshio Ariyasu , Tsunetaka Ohta
IPC分类号： C07K16/24 , G01N33/566 , C07K1/22 , C12N5/16
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/76 , G01N33/6866 , G01N2030/8831
摘要： The present invention has the first object to provide a monoclonal antibody specific to interferon α subtype α8 (IFNα8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFNα8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFNα8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8. The present invention solves the above objects by providing a monoclonal antibody specific to IFNα8 and its mutant proteins, a hybridoma capable of producing the monoclonal antibody, a method for detecting the IFNα8 and its mutant proteins by immunoreaction using the monoclonal antibody, a method for purifying the IFNα8 and its mutant proteins using the monoclonal antibody, and a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8, which contains the monoclonal antibody as an effective ingredient.
摘要翻译：本发明的第一个目的是提供对干扰素α亚型α8（IFNα8）及其突变蛋白特异性的单克隆抗体，第二个目的是提供能产生单克隆抗体的杂交瘤，第三个目的是提供一种检测方法通过单克隆抗体IFNα8及其突变蛋白，第四个目的是提供通过单克隆抗体纯化IFNα8及其突变蛋白的方法，第五个目的是提供一种用于治疗其发作或加重与IFNα8相关的疾病的治疗剂。本发明通过提供对IFNα8及其突变蛋白特异性的单克隆抗体，能够产生单克隆抗体的杂交瘤，通过使用单克隆抗体的免疫反应检测IFNα8及其突变蛋白的方法来解决上述目的，纯化方法使用单克隆抗体的IFNα8及其突变蛋白，以及用于治疗其发作或恶化与IFNα8相关的疾病的治疗剂，其含有单克隆抗体作为有效成分。

7. 发明授权

US5827691A Process for preparing a protein which inhibits metastasis of cancer 失效
标题翻译：制备抑制癌转移的蛋白质的方法
公开(公告)号：US5827691A
公开(公告)日：1998-10-27
申请号：US827864
申请日：1997-04-09
申请人： Kanso Iwaki , Tsunetaka Ohta , Masashi Kurimoto
发明人： Kanso Iwaki , Tsunetaka Ohta , Masashi Kurimoto
IPC分类号： A61K38/00 , A61P35/00 , A61P35/04 , C07K14/47 , C12N5/06 , C12N15/09 , C12N15/12 , C12P21/02 , C12R1/91
CPC分类号： C07K14/4703 , A61K38/00
摘要： Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Guerin and lipopolysaccharide.
摘要翻译：公开了一种新型蛋白质，其分子量为45,000 +/- 5,000，pI 5.7 +/- 0.5，具有癌转移抑制活性。蛋白质可以通过培养能够在营养培养基中产生蛋白质的人细胞，动物细胞和微生物，同时用诸如Baccal Calmette-Gu + E，acu e + EE rin和脂多糖的诱导剂刺激它们来制备。

8. 发明申请

US20120035187A1 ANTI-NEURODEGENERATIVE DISEASE AGENT 审中-公开
标题翻译：抗神经病变药物
公开(公告)号：US20120035187A1
公开(公告)日：2012-02-09
申请号：US13146840
申请日：2010-01-25
申请人： Hitomi Ohta , Kenji Akita , Tsunetaka Ohta , Toshio Kawata , Shigeharu Fukuda
发明人： Hitomi Ohta , Kenji Akita , Tsunetaka Ohta , Toshio Kawata , Shigeharu Fukuda
IPC分类号： A61K31/496 , C07D417/14 , C07D263/57 , C07D213/38 , C07D417/06 , C07D413/06 , C07D403/06 , C07D403/14 , A61K31/4709 , A61K31/427 , A61K31/428 , A61K31/423 , A61K31/44 , A61K31/404 , A61P25/00 , A61P25/28 , A61P25/16 , A61P3/10 , A61P27/02 , A61P35/04 , A61P17/04 , A61P39/06 , A61P35/00 , C07D401/14
CPC分类号： C07D277/22 , C07D209/14 , C07D213/74 , C07D215/06 , C07D215/12 , C07D231/22 , C07D235/20 , C07D261/12 , C07D263/56 , C07D277/28 , C07D277/64 , C07D277/84 , C07D311/74 , C07D333/32 , C07D333/64 , C07D405/06 , C07D413/06 , C07D417/06
摘要： The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1: wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; represents an integer of 0, 1 or 2; p represents an integer of 0 or 1, with the proviso that p is 1 when o is 0 or 2, and p is 0 when o is 1; R1 and R2 do not exist when o is 0, while, when p is 0, R3 does not exist and the binding between the carbon atom to which R2 binds and Z2 is a single bond; X1− represents an appropriate counter anion and q represents an integer of 1 or 2.
摘要翻译：本发明的目的是提供抗神经退行性疾病的新型药剂，通过提供含有下述通式1表示的化合物作为有效成分的抗神经变性疾病试剂来解决本发明的目的：其中在通式1中，R 1至R 3独立地表示氢原子或适当的取代基; Z1表示杂环，Z2表示与Z1中相同或不同的杂环或芳环，其中杂环和芳环任选具有取代基; 表示0,1或2的整数; p表示0或1的整数，条件是当o为0或2时p为1，当o为1时p为0; 当o为0时，R1和R2不存在，而当p为0时，R3不存在，R2结合的碳原子与Z2为单键的结合; X 1表示适当的抗衡阴离子，q表示1或2的整数。

9. 发明申请

US20110293555A1 TUMOR NECROSIS FACTOR-ALPHA MUTANTS 有权
标题翻译：肿瘤坏死因子-ALPHA突变体
公开(公告)号：US20110293555A1
公开(公告)日：2011-12-01
申请号：US13205053
申请日：2011-08-08
申请人： TADANORI MAYUMI , YASUO TSUTSUMI , SHINSAKU NAKAGAWA , TSUNETAKA OHTA
发明人： TADANORI MAYUMI , YASUO TSUTSUMI , SHINSAKU NAKAGAWA , TSUNETAKA OHTA
IPC分类号： A61K38/19 , A61P31/00 , C07K14/525
CPC分类号： A61K38/191 , C07K14/525 , Y02A50/411
摘要： The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.
摘要翻译：本发明的目的是提供肿瘤坏死因子突变蛋白，特别是TNF-R1或TNF-R2特异的肿瘤坏死因子突变体蛋白; 肿瘤坏死因子抑制剂; 或含有其作为有效成分的肿瘤坏死因子制剂，其目的是通过提供一种或多种选自第29,31,32,35,146和147位的氨基酸残基的肿瘤坏死因子突变蛋白来解决，或由SEQ ID NO：1的氨基酸序列的N末端第84位至第89位的基团被其它氨基酸残基取代; 肿瘤坏死因子抑制剂; 和含有它作为有效成分的肿瘤坏死因子制剂。

10. 发明授权

US5731193A Recombinant DNA and transformant containing the same 失效
标题翻译：重组DNA和含有其的转化体
公开(公告)号：US5731193A
公开(公告)日：1998-03-24
申请号：US828511
申请日：1997-03-31
申请人： Tetsuya Mori , Kozo Yamamoto , Tsunetaka Ohta
发明人： Tetsuya Mori , Kozo Yamamoto , Tsunetaka Ohta
IPC分类号： C12N15/09 , C07K14/505 , C07K14/56 , C12N5/10 , C12N15/85 , C07H21/04 , C12N15/67 , C12P21/02
CPC分类号： C12N15/85 , C07K14/505 , C07K14/56 , C12N2830/00 , C12N2830/42 , C12N2830/85
摘要： Insertion of IFN-alpha promoters in recombinant DNAs improves their expression efficiencies for useful polypeptides. Expression of such a recombinant DNA in host cells of mammalian origin is artificially controllable by the presence and absence of external stimuli using IFN-alpha inducers. Thus, transformants with such a recombinant DNA readily increase to a maximized cell density with causing neither damages nor extinction due to polypeptides they produce, and subsequent exposure to IFN-alpha inducers allows the proliferated cells to efficiently produce polypeptides with significant glycosylations.
摘要翻译：在重组DNA中插入IFN-α启动子改善了其对有用多肽的表达效率。这种重组DNA在哺乳动物来源的宿主细胞中的表达可以通过使用IFN-α诱导物的外部刺激的存在和不存在来人为可控。因此，具有这种重组DNA的转化体容易增加到最大化的细胞密度，由于它们产生的多肽而不造成损伤或消灭，随后暴露于IFN-α诱导物允许增殖的细胞有效地产生具有显着糖基化的多肽。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式